|
|
 |
|
Viewing report
|
|
|
|
Global Pipeline Review & Analysis of Hematological Malignancies
Bioseeker, March 2007, Pages: 195
Introduction
The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
About this report
In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, the author reports on the hematological cancer pipeline by:
Investigator - Includes 212 investigators and partners
Drug - Includes 237 'active' drugs
Sub-indication - Includes 11 sub-indications
Developmental stage - Includes 8 developmental stages
Compound type - Includes 21 different compounds types
Targeted therapy strategy - Includes 5 different targeted therapy strategies
Target - Includes 97 different protein targets
Signaling pathway - Includes 18 different signaling pathways
All of above 'factors' are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each 'factor' included in this cutting edge analysis.
Investigator
This report includes 212 investigators and partners from all over the world.
Drug
There are today more than 237 therapeutics for the treatment of hematological cancers, from early preclinical to marketed drugs. Each drug is annotated with a brief drug description.
Sub-indication
The hematological cancer drug pipeline is broken down into 11 sub-indications:
Cancer, leukemia, acute lymphocytic
Cancer, leukemia, acute myelogenous
Cancer, leukemia, chronic lymphocytic
Cancer, leukemia, chronic myelogenous
Cancer, leukemia, general
Cancer, leukemia, hairy cell
Cancer, lymphoma, B-cell
Cancer, lymphoma, general
Cancer, lymphoma, Hodgkin`s
Cancer, lymphoma, non-Hodgkin`s
Cancer, lymphoma, T-cell
Only the highest developmental stage per drug and indication is accounted for.
Developmental Stage
Each sub-indication of a drug is described with its developmental stage:
Preclinical
Clinical Trial
Phase I Clinical Trial
Phase II Clinical Trial
Phase III Clinical Trial
Pre-registration
Registered
Marketed
Compound Type
We have described all 237 drugs in the hematological malignancies pipeline with its corresponding compound type:
Biological
Biological, bacterial cells
Biological, cellular, autologous
Biological, cellular, heterologous
Biological, nucleic acid
Biological, nucleic acid, non-viral vector
Biological, nucleic acid, viral vector
Biological, peptide
Biological, peptide, recombinant
Biological, protein
Biological, protein, antibody
Biological, protein, recombinant
Chemical, semisynthetic
Chemical, synthetic
Chemical, synthetic, isomeric
Chemical, synthetic, nucleic acid
Chemical, synthetic, peptide
Natural product
Natural product, animal
Natural product, bacterial
Natural product, plant
When available, drug compounds are further described with chemical name, CAS number, chemical formula and molecular weight.
Targeted Therapy Strategy
This report categorizes available drugs into 5 major targeted therapy strategies:
1.Angiogenesis
2. Antibody
3. Apoptosis
4. Protein Kinase Inhibitors
5. Vaccines
Target
This analysis includes 97 protein targets, linked to 165 drugs for the treatment of hematological cancers. All protein targets are described by its primary localization, molecular class, molecular function, and biological process:
Primary Localization of Target:
Cell surface
Centrosome
Cytoplasm
Cytosol
Endoplasmic reticulum
Extracellular
Integral to membrane
Lysosome
Mitochondrial membrane
Mitochondrion
Nucleus
Plasma membrane
Secretory granule
Molecular Class of Target:
Adapter molecule
Adhesion molecule
Cell cycle control protein
Cell surface receptor
Chaperone
Cysteine protease
Cytokine
Cytokine receptor
Cytoskeletal protein
DNA methyltransferase
DNA polymerase
DNA repair protein
Enzyme: Deaminase
Enzyme: Decarboxylase
Enzyme: Hydrolase
Enzyme: Ligase
Enzyme: Oxidoreductase
Enzyme: Phosphorylase
Enzyme: Topoisomerase
Enzyme: Transferase
G protein coupled receptor
Growth factor
Integral membrane protein
Ligand
Lipid phosphatase
Membrane bound ligand
MHC complex protein
Nuclear receptor
Receptor tyrosine kinase
Serine protease
Serine/threonine kinase
T cell antigen receptor
Transcription factor
Transcription regulatory protein
Translation regulatory protein
Transport/cargo protein
Tyrosine kinase
Unclassified
Molecular Function of Target:
Carboxy-lyase activity
Cell adhesion molecule activity
Chaperone activity
Cysteine-type peptidase activity
Cytokine activity
Deaminase activity
DNA repair protein
DNA topoisomerase activity
DNA-directed DNA polymerase activity
DNA-methyltransferase activity
G-protein coupled receptor activity
Growth factor activity
Hydrolase activity
Kinase activity
Ligand-dependent nuclear receptor activity
Ligase activity
Lipid phosphatase activity
MHC class I receptor activity
Molecular function unknown
Oxidoreductase activity
Phosphorylase activity
Protein binding
Protein serine/threonine kinase activity
Protein-tyrosine kinase activity
Receptor activity
Receptor binding
Receptor signaling complex scaffold activity
Serine-type peptidase activity
Structural constituent of cytoskeleton
T cell receptor activity
Transcription factor activity
Transcription regulator activity
Transferase activity
Translation regulator activity
Transmembrane receptor activity
Transmembrane receptor protein tyrosine kinase activity
Transporter activity
Unclassified
Biological Process of Target:
Anti-apoptosis
Apoptosis
Cell communication
Cell communication ; Cell surface receptor linked signal transduction
Cell communication ; Signal transduction
Cell communication ; Signal transduction ; Transport
Cell growth and/or maintenance
Enzyme linked receptor protein signaling pathway ; Cellular morphogenesis during differentiation
Immune response
Metabolism
Metabolism; Energy pathways
Protein metabolism
Protein modification
Regulation of cell cycle
Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
Signal transduction
Transport
Signaling Pathway
The 97 available protein targets have been compared with molecular entities in known signaling pathways. This analysis showed the involvement of hematological drugs in at least 18 different signaling pathways:
Alpha6 Beta4 Integrin Signaling Pathway
Androgen Receptor Signaling Pathway
B Cell Receptor Signaling Pathway
EGFR1 Signaling Pathway
ID Signaling Pathway
IL-1 Singaling Pathway
IL-2 Signaling Pathway
IL-3 Signaling Pathway
IL-4 Signaling Pathway
IL-5 Signaling Pathway
IL-6 Signaling Pathway
IL-7 Signaling Pathway
Kit Receptor Signaling Pathway
Notch Signaling Pathway
T Cell Receptor Signaling Pathway
TGF-beta Receptor Signaling Pathway
TNF-alpha Signaling Pathway
Wnt Signaling Pathway
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
